Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 252

Results For "LA"

7434 News Found

LupinLife Launches ayurvedic energy supplement
News | February 12, 2021

LupinLife Launches ayurvedic energy supplement

Be One is a 100% Ayurvedic health and wellness supplement.


Jubilant Pharmova Q3FY21 consolidated PAT at Rs. 309.93 Cr
News | February 08, 2021

Jubilant Pharmova Q3FY21 consolidated PAT at Rs. 309.93 Cr

The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.


Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr
News | February 06, 2021

Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr

The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.


GlaxoSmithKline Pharmaceuticals Q3FY21 consolidated PAT at Rs. 156.51 Cr
News | February 06, 2021

GlaxoSmithKline Pharmaceuticals Q3FY21 consolidated PAT at Rs. 156.51 Cr

The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.


WACKER acquires plasmid DNA Manufacturer Genopis
News | February 05, 2021

WACKER acquires plasmid DNA Manufacturer Genopis

WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).


Biocon Biologics to offer its oncology biosimilars in 30+ countries
Biotech | February 05, 2021

Biocon Biologics to offer its oncology biosimilars in 30+ countries

The partnership is a significant step in delivering advanced cancer therapies to patients.


Dr. Reddy's Laboratories reports Rs. 19.8 Cr PAT in Q3FY21
News | February 01, 2021

Dr. Reddy's Laboratories reports Rs. 19.8 Cr PAT in Q3FY21

The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.


CIPLA Q3 FY21 PAT up to Rs. 748.15 Cr
News | February 01, 2021

CIPLA Q3 FY21 PAT up to Rs. 748.15 Cr

The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.


Laurus Q3 FY21 revenue up 76%; PAT grows 274%
News | January 29, 2021

Laurus Q3 FY21 revenue up 76%; PAT grows 274%

The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.


Slow recovery in biosimilars for Biocon: ICICI Securities
News | January 26, 2021

Slow recovery in biosimilars for Biocon: ICICI Securities

Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.